Dispensing doctors and the Single National Formulary: A more complex picture

Dispensing practices have rarely featured in the wave of commentary that followed the Single National Formulary announcement. Most of the analysis has concentrated on Integrated Care Boards, NICE sequencing and market access pipelines. Yet dispensing practices sit in a different position to the rest of primary care, operate under a different commercial logic, and are facing a more complicated set of simultaneous pressures than the SNF debate alone would suggest.

There are 935 dispensing practices in England, covering 9.54 million registered patients across England, Scotland and Wales combined. Dispensing doctors provide primary care services to around 10 million patients and dispense medicines to approximately 3.5 million, around 7% of the population. Almost all are in rural or semi-rural areas. For those patients, the dispensing practice is not a convenient option; it is usually the only local source of NHS medicines. That access dependency is part of why this segment deserves more attention than it typically receives.

How dispensing practices make formulary decisions

A dispensing doctor is a GP who both prescribes and dispenses medicines directly to patients. The eligibility criteria are specific: the patient must live more than 1.6km from a community pharmacy, the practice must be in an approved rural location, and the patient must be registered on the practice’s dispensing list. The GMS contract governs the clinical obligations, but the commercial realities are a different matter.

The financial model turns on clawback. The NHS reimburses dispensing practices for medicines dispensed, but deducts 11.18% of the NHS list price, assuming that practices receive manufacturer discounts. That rate applies regardless of whether a discount was obtained, so any product bought without a discount is dispensed at a loss. The margin between actual purchase price and clawback-adjusted reimbursement is what makes dispensing financially viable, which is why manufacturer discount schemes are the primary commercial consideration for this segment.

Within that context, dispensing practices review their formularies in response to a recognisable set of triggers: new clinical evidence, NICE recommendations, significant price changes in a therapeutic group, new products or formulations becoming available, patent expiry, and changes to the dispensing deal. Pharma contact and marketing play a role alongside those factors. What is notable currently is that the SNF, Category H, and ongoing ICB prescribing pressure are moving several of these triggers at once.

For a detailed look at the fundamentals of engaging this segment, our earlier post on marketing pharmaceuticals to dispensing doctors covers the basics.

Category H: the other reimbursement reform

The SNF is not the only policy change affecting how dispensing practices are reimbursed. From March 2026, the NHS introduced Category H, a new classification within Part VIIIA of the Drug Tariff. It applies to generic products in Category C with multiple suppliers, where the historical reimbursement price was set against a single reference brand that no longer reflects current market prices. Under Category H, reimbursement is recalculated quarterly using weighted sales and volume data from manufacturers and wholesalers.

The first wave covered 11 products. Of those, five saw reimbursement prices fall, and six saw them rise. The next batch is due in June 2026, and over 100 Category C products with multiple suppliers are potentially eligible for migration. Community Pharmacy England has objected to the pace of the rollout, citing supply chain instability. The Dispensing Doctors’ Association has noted that the change applies equally to dispensing practices.

For dispensing practices, Category H is consequential because it changes the reimbursement arithmetic on products where the discount-versus-clawback calculation has been a known quantity. When a product moves from Category C to Category H, the reimbursement price shifts, and the margin on that product changes with it. Where a discount scheme is tied to a Category C product that subsequently moves to Category H, the commercial proposition for the practice may no longer be the same.

Both Category H and the SNF point in the same direction: tighter alignment between NHS reimbursement and actual market prices. For pharma and medtech companies, that direction of travel should inform how discount schemes are structured and presented, not just for new products but for existing ones in the pipeline for tariff reclassification.

The ICB pressure layer

Dispensing practices are already managing a tension that the SNF will intensify. ICBs and primary care networks commission prescribing support tools, including ScriptSwitch and OptimizeRx, which intervene at the point of prescribing with formulary-based recommendations. These tools are installed on GP prescribing systems, paid for by the ICB, and flag preferred alternatives when a prescriber is about to issue a script. The prescriber retainsclinical discretion, but their choices are monitored.

In a standard GP practice, ICB formulary preferences and prescribing economics point in the same direction. In a dispensing practice, they can point in opposite directions. An ICB may want a practice to switch from a profitable branded inhaler to a cheaper generic alternative, but the practice has a legitimate commercial interest in the current product. Managing that tension, prescribing with probity while running a viable dispensary, is an ongoing challenge for dispensing practices that most NHS policy discussions, including the early SNF commentary, have not addressed.

The SNF adds a national layer to that existing ICB-level pressure. As therapeutic area decisions are released from July 2026 and ICBs align their local guidance accordingly, the range of products that prescribing support tools flag as preferred will narrow. For products that sit outside the SNF’s preferred sequencing, the commercial case will become harder to make at practice level, not through any single intervention but through the cumulative weight of national guidance, local formulary alignment and point-of-prescribing prompts.

The stakeholder map

Effective engagement with dispensing practices requires understanding a management structure that varies considerably by practice size. The core stakeholders are the prescribing GP, the dispensary manager and the practice or business manager. In larger practices and group structures, that layer often splits further: a business manager focused on financial performance and procurement, and an operations manager focused on staffing and patient services. Chief executives are increasingly common in larger dispensing groups.

Each stakeholder has different priorities in the current environment. The GP will be focused on clinical evidence, NICE guidance and the direction of the national formulary. The dispensary manager and business manager are tracking margin per item dispensed, the impact of Category H on their existing product mix, and whether current wholesaler arrangements and discount schemes remain viable as reimbursement prices shift. Our post on the evolving role of the practice manager, based on a direct interview, explores that management layer in depth.

Dispensary teams themselves are tightly embedded in practice culture and operations. PCN clinical pharmacists and external partners working with these practices find that earning the trust of the dispensary team is as important as engaging the prescriber. For pharma field teams, the same applies: understanding the commercial model and being able to speak to it directly, rather than treating it as background context, is what distinguishes effective engagement in this segment from generic GP advice.

The window before the framework solidifies

The SNF digital tool launches in July 2027 in a select range of therapeutic areas, expanding to cover further areas, including medtech, by 2030. Final national guidance is expected in December 2026. Therapeutic area decisions begin from July 2026. That sequence gives a meaningful window for companies that understand the dispensing doctor segment to establish or consolidate their position before national sequencing makes the commercial conversation significantly harder.

Practical priorities for that window:

• Know where your product sits in the SNF pipeline: Therapeutic area sequencing begins in July 2026. Understanding your product’s likely position in the national formulary and being able to discuss that with practice managers and dispensary managers is now a basic requirement for field teams working in this segment.

• Audit your Category H exposure: If you have products currently in Category C with multiple suppliers, assess whether they are candidates for migration to Category H and what that means for the discount schemes you offer.

• Revisit the discount conversation: With reimbursement prices shifting under Category H and SNF sequencing beginning to signal preferred products nationally, practices will review whether existing discount arrangements remain competitive. That review is an opportunity for companies that engage proactively.

• Map the full stakeholder picture: In a period of structural change, the business manager and dispensary manager are as important as the prescriber. The commercial conversation and the clinical conversation need to be coordinated, not sequential.

For practices navigating the transition

The planning questions for dispensing practices themselves are not straightforward. How does the SNF’s preferred sequencing interact with existing procurement arrangements? What happens to the margin on Category H products as the reimbursement price is recalculated quarterly? How should the practice position itself with the ICB as national formulary guidance begins to arrive?

Dispensing practices that conduct a structured review of their dispensary economics in the next 12 months, before national guidance crystallises, will be better placed than those that respond to each change as it arrives. Medacy, CHASE’s sister company, works with dispensing practices on exactly this kind of business analysis and process review. Details are at medacy.co.uk/dispensing-doctors-support.

Conclusion

The SNF is arriving into a segment that is already managing more complexity than most NHS commentary acknowledges: a financial model under pressure from zero fee uplifts and Category H reimbursement changes, an ICB prescribing layer that can conflict with commercial viability, and a patient population of nearly 10 million people in rural England who depend on these practices as their primary medicines access point.

The companies and practices that treat these pressures as a connected picture, rather than responding to each policy development in isolation, are the ones best placed to navigate the next 18 months.

CHASE works with pharmaceutical and medtech companies developing their commercial strategy for the dispensing doctor segment, including outsourced field teams with specific expertise in this area. Get in touch to discuss what the current environment means for your organisation.